Clinical trialNCT05886036RecruitingPhase 2Interventional

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial

SponsorNational Cancer Institute (NCI)Enrollment70Nodular Lymphocyte Predominant B-Cell LymphomaRecurrent Nodular Lymphocyte Predominant B-Cell LymphomaRefractory Nodular Lymphocyte Predominant B-Cell Lymphoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial compares mosunetuzumab to the usual treatment (rituximab) for improving survival in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Rituximab and mosunetuzumab are monoclonal antibodies. They bind to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab may be more effective at extending survival in patients with NLPHL than the usual approach with rituximab.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Raphael E Steiner
University of Texas MD Anderson Cancer Center LAO
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

37 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

University Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada
Suspended

United States

City of Hope Comprehensive Cancer Center
Duarte, California, United States
Alex F. Herrera
Recruiting
Um Sylvester Comprehensive Cancer Center at Aventura
Aventura, Florida, United States
Michele Stanchina
Recruiting
Um Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida, United States
Michele Stanchina
Recruiting
Um Sylvester Comprehensive Cancer Center at Coral Springs
Coral Springs, Florida, United States
Michele Stanchina
Recruiting
Um Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida, United States
Michele Stanchina
Recruiting
Um Sylvester Comprehensive Cancer Center at Doral
Doral, Florida, United States
Michele Stanchina
Recruiting
Um Sylvester Comprehensive Cancer Center at Hollywood
Hollywood, Florida, United States
Michele Stanchina
Recruiting
Um Sylvester Comprehensive Cancer Center at Kendall
Miami, Florida, United States
Michele Stanchina
Recruiting
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, United States
Michele Stanchina
Recruiting
University of Miami Sylvester Comprehensive Cancer Center at Sole Mia
North Miami, Florida, United States
Michele Stanchina
Recruiting
Um Sylvester Comprehensive Cancer Center at Plantation
Plantation, Florida, United States
Michele Stanchina
Recruiting
Emory University Hospital/winship Cancer Institute
Atlanta, Georgia, United States
Active, not recruiting
University of Kansas Cancer Center
Kansas City, Kansas, United States
Marc S. Hoffmann
Recruiting
University of Kansas Cancer Center-Overland Park
Overland Park, Kansas, United States
Marc S. Hoffmann
Recruiting
University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas, United States
Marc S. Hoffmann
Recruiting
University of Kansas Cancer Center - Briarcliff
Kansas City, Missouri, United States
Marc S. Hoffmann
Recruiting
University of Kansas Cancer Center - North
Kansas City, Missouri, United States
Marc S. Hoffmann
Recruiting
University of Kansas Cancer Center - Lee'S Summit
Lee's Summit, Missouri, United States
Marc S. Hoffmann
Recruiting
University of Kansas Cancer Center at North Kansas City Hospital
North Kansas City, Missouri, United States
Suspended
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, United States
Raphael E. Steiner
Recruiting
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States
Raphael E. Steiner
Recruiting
Memorial Sloan Kettering Bergen
Montvale, New Jersey, United States
Raphael E. Steiner
Recruiting
Memorial Sloan Kettering Commack
Commack, New York, United States
Raphael E. Steiner
Recruiting
Memorial Sloan Kettering Westchester
Harrison, New York, United States
Raphael E. Steiner
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Raphael E. Steiner
Recruiting
Memorial Sloan Kettering Nassau
Uniondale, New York, United States
Raphael E. Steiner
Recruiting
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
Rakhee Vaidya
Recruiting
University of Cincinnati Cancer Center-Uc Medical Center
Cincinnati, Ohio, United States
Zulfa Omer
Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Yun Choi
Recruiting
University of Cincinnati Cancer Center-West Chester
West Chester, Ohio, United States
Zulfa Omer
Recruiting
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Sami Ibrahimi
Recruiting
Upmc Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Active, not recruiting
Ut Md Anderson Cancer Center
Houston, Texas, United States
Dai Chihara
Recruiting
Huntsman Cancer Institute/university of Utah
Salt Lake City, Utah, United States
Allison Bock
Recruiting
University of Virginia Cancer Center
Charlottesville, Virginia, United States
Nathan L. Roberts
Recruiting
Vcu Massey Comprehensive Cancer Center
Richmond, Virginia, United States
Bruce O. Hough
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Mosunetuzumab →Rituximab →Rituximab and Hyaluronidase Human

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 23 Jan 2024
Primary completion: 31 Oct 2026
Completion: 31 Oct 2026
Last update posted: 5 Aug 2026
Registered enrollment: 70
Registry id: NCT05886036

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.